Keyword Analysis & Research: ruxolitinib phosphate treatment


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
ruxolitinib phosphate treatment1.390.8604510031
ruxolitinib0.670.370859111
phosphate1.870.38212869
treatment1.391966419

Keyword Research: People who searched ruxolitinib phosphate treatment also searched

Keyword CPC PCC Volume Score
ruxolitinib phosphate treatment1.410.417559

Search Results related to ruxolitinib phosphate treatment on Search Engine

  • Ruxolitinib Phosphate - National Cancer Institute

    cancer.gov

    https://www.cancer.gov/about-cancer/treatment/drugs/ruxolitinibphosphate

    Ruxolitinib phosphate is approved for use in adults to treat: Myelofibrosis (a bone marrow disease) that is intermediate risk or high risk, including the following types: Primary myelofibrosis. Post-polycythemia vera myelofibrosis. Post-essential thrombocythemia myelofibrosis.

    DA: 27 PA: 34 MOZ Rank: 49

  • Ruxolitinib phosphate | C17H21N6O4P - PubChem

    nih.gov

    https://pubchem.ncbi.nlm.nih.gov/compound/Ruxolitinib-phosphate

    Ruxolitinib phosphate is a phosphate salt obtained by reaction ruxolitinib with one equivalent of phosphoric acid. Used for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.

    DA: 11 PA: 29 MOZ Rank: 19

  • Clinical Trials Using Ruxolitinib Phosphate - National ...

    cancer.gov

    https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/ruxolitinib-phosphate

    Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, doxorubicin hydrochloride, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

    DA: 6 PA: 52 MOZ Rank: 85

  • Ruxolitinib Monograph for Professionals - Drugs.com

    drugs.com

    https://www.drugs.com/monograph/ruxolitinib.html

    Available as ruxolitinib phosphate; dosage expressed in terms of ruxolitinib. 1. Adults Intermediate- or High-Risk Myelofibrosis Oral. Platelet count >200,000/mm 3: Initially, 20 mg twice daily. 1. Platelet count 100,000–200,000/mm 3: Initially, 15 mg twice daily. 1

    DA: 58 PA: 69 MOZ Rank: 97

  • Jakafi (ruxolitinib) dosing, indications, interactions ...

    medscape.com

    https://reference.medscape.com/drug/jakafi-ruxolitinib-999703

    Treatment interruption in patients starting treatment with a platelet count 50 to . 75 x10^9/L Interrupt treatment for platelet count ; 25 x 10^9/L or ANC less than 0.5 X 10^9/L After recovery of platelet count >35 X 10^9/L and ANC >0.75 X 10^9/L, dosing may be restarted

    DA: 69 PA: 33 MOZ Rank: 40


  • Ruxolitinib: Indications, Side Effects, Warnings - Drugs.com

    drugs.com

    https://www.drugs.com/cdi/ruxolitinib.html

    Those who have feeding tubes may also use the tablet. Mix each tablet with 40 mL of water. Stir for 10 minutes. Give within 6 hours of mixing. Flush the feeding tube with water before and after ruxolitinib is given. If you are on dialysis and are taking ruxolitinib on the day you get dialysis, take it after your dialysis.

    DA: 37 PA: 11 MOZ Rank: 6

  • Ruxolitinib for treatment of refractory hemophagocytic ...

    ashpublications.org

    https://ashpublications.org/bloodadvances/article/1/19/1533/15667/Ruxolitinib-for-treatment-of-refractory

    Ruxolitinib 2.5 mg twice per day was started based on dosing used for graft-versus-host disease treatment. 6,7 Within 24 hours of starting ruxolitinib, our patient became afebrile, with rapid improvement in respiratory, liver, and hemodynamic function, improvement in inflammatory markers, and decrease in transfusion requirements . He no longer ...

    DA: 56 PA: 91 MOZ Rank: 89

  • Ruxolitinib Phosphate and Azacytidine in Treating Patients ...

    aamds.org

    https://www.aamds.org/treatments/clinical-trials/ruxolitinib-phosphate-and-azacytidine-treating-patients-myelofibrosis-or

    This phase II trial studies how well ruxolitinib phosphate and azacytidine work in treating patients with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacytidine, work in different ways to stop the growth of cancer ...

    DA: 89 PA: 11 MOZ Rank: 61

  • A Study of Ruxolitinib for the Treatment of Graft-Versus ...

    mayo.edu

    https://www.mayo.edu/research/clinical-trials/cls-20467383

    About this study. The purpose of this study is to provide ruxolitinib through an expanded access program in the United States for the treatment of graft-versus-host disease (GVHD) in patients who are ineligible or unable to participate in any actively enrolling Incyte-sponsored clinical studies for ruxolitinib in the treatment of GVHD.

    DA: 30 PA: 11 MOZ Rank: 76